Equities analysts expect AxoGen, Inc. (NASDAQ:AXGN) to report sales of $16.06 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for AxoGen’s earnings, with estimates ranging from $16.01 million to $16.10 million. AxoGen reported sales of $11.41 million in the same quarter last year, which would suggest a positive year over year growth rate of 40.8%. The company is expected to issue its next earnings report on Wednesday, February 28th.

On average, analysts expect that AxoGen will report full-year sales of $16.06 million for the current fiscal year, with estimates ranging from $59.46 million to $59.60 million. For the next financial year, analysts forecast that the firm will report sales of $83.55 million per share, with estimates ranging from $83.30 million to $83.80 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for AxoGen.

AxoGen (NASDAQ:AXGN) last issued its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported ($0.06) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.06). The firm had revenue of $16.05 million for the quarter, compared to analysts’ expectations of $15.55 million. AxoGen had a negative net margin of 24.74% and a negative return on equity of 91.00%. AxoGen’s revenue was up 43.2% on a year-over-year basis.

Several equities research analysts have issued reports on the stock. Leerink Swann raised their price target on shares of AxoGen from $23.00 to $26.00 and gave the stock an “outperform” rating in a research note on Thursday, November 2nd. Roth Capital reaffirmed a “buy” rating and set a $21.00 price target (up from $18.00) on shares of AxoGen in a research note on Tuesday, September 12th. BidaskClub cut shares of AxoGen from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $18.00 price target on shares of AxoGen in a research note on Monday, August 21st. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. AxoGen currently has a consensus rating of “Buy” and an average target price of $18.00.

ILLEGAL ACTIVITY NOTICE: “AxoGen, Inc. (AXGN) Expected to Post Quarterly Sales of $16.06 Million” was originally posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/axogen-inc-axgn-expected-to-post-quarterly-sales-of-16-06-million/1702306.html.

Shares of AxoGen (NASDAQ AXGN) opened at $24.80 on Tuesday. AxoGen has a 12 month low of $8.05 and a 12 month high of $25.15. The company has a debt-to-equity ratio of 1.93, a quick ratio of 2.95 and a current ratio of 3.55.

In related news, Director Robert James Rudelius sold 16,143 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $18.00, for a total value of $290,574.00. Following the transaction, the director now owns 43,273 shares in the company, valued at $778,914. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 9.33% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of AXGN. Bank of America Corp DE raised its holdings in AxoGen by 8.7% in the first quarter. Bank of America Corp DE now owns 10,183 shares of the medical equipment provider’s stock valued at $106,000 after buying an additional 814 shares during the period. Parametric Portfolio Associates LLC raised its holdings in AxoGen by 0.9% in the first quarter. Parametric Portfolio Associates LLC now owns 10,843 shares of the medical equipment provider’s stock valued at $113,000 after buying an additional 93 shares during the period. Thompson Davis & CO. Inc. raised its stake in shares of AxoGen by 575.0% during the second quarter. Thompson Davis & CO. Inc. now owns 6,750 shares of the medical equipment provider’s stock valued at $113,000 after purchasing an additional 5,750 shares during the period. American International Group Inc. raised its stake in shares of AxoGen by 7.7% during the first quarter. American International Group Inc. now owns 14,941 shares of the medical equipment provider’s stock valued at $156,000 after purchasing an additional 1,068 shares during the period. Finally, UBS Group AG raised its stake in shares of AxoGen by 8.3% during the first quarter. UBS Group AG now owns 16,141 shares of the medical equipment provider’s stock valued at $169,000 after purchasing an additional 1,234 shares during the period. Hedge funds and other institutional investors own 67.44% of the company’s stock.

AxoGen Company Profile

AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The company’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Get a free copy of the Zacks research report on AxoGen (AXGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.